Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05248360
Other study ID # JD-LK-2021-100-03
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date October 11, 2022
Est. completion date December 31, 2023

Study information

Verified date December 2022
Source Second Affiliated Hospital of Soochow University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of hydrogen-oxygen mixed gas inhalation in the treatment of insomnia.


Description:

This ia a randomized, double-blind, crossover, placebo-controlled Study. The purpose is to evaluate the efficacy and safety of hydrogen-oxygen mixed gas(H2-O2) inhalation in the treatment of insomnia, and explore the possible mechanism by detecting the changes of serum inflammatory factors (CRP, IL-6, IL-1β, TNF-α) levels, so as to seek an effective therapy for insomnia.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 40
Est. completion date December 31, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Diagnosed of insomnia according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). 2. No use of sleep medications within the preceding 2 weeks, or a stable dose of only one sedative hypnotic medicine for at least 1 month before the enrollment and remain unchanged throughout the course of the study. 3. Signed informed consent form (ICF). Exclusion Criteria: 1. Complicated with other sleep disorders (sleep apnea syndrome, narcolepsy, restless legs syndrome, nocturia, etc.); 2. Complicated with serious heart, lung, liver or renal diseases or malignant tumor; 3. History of mental illness; 4. Drugs or substances abuse; 5. Pregnant women, breast-feeding women or those with recent birth plans; 6. Participants in other clinical trials within 1 month before the study.

Study Design


Related Conditions & MeSH terms

  • Insomnia
  • Sleep Initiation and Maintenance Disorders

Intervention

Device:
Hydrogen-oxygen mixed gas(H2-O2) inhalation
H2-O2 inhalation, 900ml/min, 2h/d * 4 weeks (=5 days/week)
Air inhalation
Air inhalation, 900ml/min, 2h/d * 4 weeks (=5 days/week)

Locations

Country Name City State
China Department of Neurology, Second Affiliated Hospital of Soochow University Suzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital of Soochow University

Country where clinical trial is conducted

China, 

References & Publications (2)

Irwin MR, Olmstead R, Carroll JE. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. Biol Psychiatry. 2016 Jul 1;80(1):40-52. doi: 10.1016/j.biopsych.2015.05.014. Epub 2015 Jun 1. — View Citation

Ohta S. Molecular hydrogen as a novel antioxidant: overview of the advantages of hydrogen for medical applications. Methods Enzymol. 2015;555:289-317. doi: 10.1016/bs.mie.2014.11.038. Epub 2015 Jan 21. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in sleep efficiency by polysomnography (PSG) at 10 weeks This outcome reflects change of patients' sleep quality. visit 1(baseline), visit 3(4th week), visit 6(10th week)
Primary Change from baseline in total sleep time by PSG at 10 weeks This outcome reflects change of patients' sleep quality. visit 1(baseline), visit 3(4th week), visit 6(10th week)
Primary Change from baseline in sleep latency by PSG at 10 weeks This outcome reflects change of patients' sleep quality. visit 1(baseline), visit 3(4th week), visit 6(10th week)
Primary Change from baseline in wake time after sleep onset by PSG at 10 weeks This outcome reflects change of patients' sleep quality. visit 1(baseline), visit 3(4th week), visit 6(10th week)
Primary Change from baseline in Insomnia Severity Index (ISI) score at 14 weeks The ISI is widely used to measure the severity of Insomnia. The ISI score ranges from 0 to 28. The higher the ISI score is, the worse the symptoms are. visit 1(baseline), visit 3(4th week), visit 4(6th week), visit 6(10th week), visit 7(14th week)
Primary Change from baseline in Pittsburgh Sleep Quality Index (PSQI) score at 14 weeks The PSQI is widely used to measure sleep quality. The PSQI score ranges from 0 to 21. The higher the PSQI score is, the worse the sleep quality is. visit 1(baseline), visit 3(4th week), visit 4(6th week), visit 6(10th week), visit 7(14th week)
Secondary Change from baseline in Hamilton Anxiety Scale (HAMA) score at 14 weeks The HAMA is a widely used interview scale to measure the severity of anxiety. The HAMA score ranges from 0 to 56. The higher the HAMA score is, the worse the symptoms are. Visit 1(baseline), visit 3(4th week), visit 4(6th week), visit 6(10th week), visit 7(14th week)
Secondary Change from baseline in Hamilton Depression Scale-17 (HAMD-17) score at 14 weeks The HAMD-17 is a test measuring the severity of depressive symptoms. The HAMA-17 score ranges from 0 to 52. The higher the HAMA score is, the worse the symptoms are. Visit 1(baseline), visit 3(4th week), visit 4(6th week), visit 6(10th week), visit 7(14th week)
Secondary Change from baseline in Mini-Mental State Examination (MMSE) score at 14 weeks The MMSE is widely used to assess cognition. The MMSE score ranges from 0 to 30. The higher the HAMA score is, the better the cognitive function is. Visit 1(baseline), visit 3(4th week), visit 4(6th week), visit 6(10th week), visit 7(14th week)
Secondary Change from baseline in Montreal Cognitive Assessment (MOCA) score at 14 weeks The MoCA is widely used to assess cognition. The HAMA-17 score ranges from 0 to 30. The higher the HAMA score is, the better the cognitive function is. Visit 1(baseline), visit 3(4th week), visit 4(6th week), visit 6(10th week), visit 7(14th week)
Secondary Change from baseline in C-reactive protein (CRP) at 10 weeks This outcome reflects change of patients' serum inflammatory factor. visit 1(baseline), visit 3(4th week), visit 6(10th week)
Secondary Change from baseline in Interleukin-6 (IL-6) at 10 weeks This outcome reflects change of patients' serum inflammatory factor. visit 1(baseline), visit 3(4th week), visit 6(10th week)
Secondary Change from baseline in Interleukin-1ß ( IL-1ß) at 10 weeks This outcome reflects change of patients' serum inflammatory factor. visit 1(baseline), visit 3(4th week), visit 6(10th week)
Secondary Change from baseline in tumor necrosis factor-a (TNF-a) at 10 weeks This outcome reflects change of patients' serum inflammatory factor. visit 1(baseline), visit 3(4th week), visit 6(10th week)
See also
  Status Clinical Trial Phase
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT05963542 - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia N/A
Completed NCT06339853 - Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia N/A
Recruiting NCT04069247 - Effectiveness of eCBT-I on Improving Mental Health in Chinese Youths With Insomnia N/A
Completed NCT04493593 - Internet-delivered CBT-I (Space for Sleep): Pilot and Feasibility N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Recruiting NCT06278077 - Neurexan - a Clinical Trial in Short-Term Insomnia Patients Phase 2
Completed NCT04661306 - The Better Sleep for Supporters With Insomnia Study N/A
Recruiting NCT06207279 - Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale
Recruiting NCT06006299 - Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC) N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT04035200 - Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation Phase 2
Active, not recruiting NCT05027438 - Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention N/A
Recruiting NCT06053840 - An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients With Severe Insomnia Phase 4
Not yet recruiting NCT06348082 - Project Women's Insomnia Sleep Health Equity Study (WISHES) N/A
Not yet recruiting NCT06363799 - Osteopathic Protocol for Insomnia in College Students N/A
Not yet recruiting NCT05991492 - Improving Sleep With a Digital Cognitive Behavioral Therapy for Insomnia Application N/A
Not yet recruiting NCT06025968 - Digital Cognitive-behavioral Therapy for Insomnia for Patients With Multiple Sclerosis N/A